Form 8-K

8-K — Aspire Biopharma Holdings, Inc.

Accession: 0001493152-26-017115

Filed: 2026-04-16

Period: 2026-04-15

CIK: 0001847345

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

GRAPHIC (ex3-1_001.jpg)

GRAPHIC (ex3-1_002.jpg)

GRAPHIC (ex3-1_003.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0001847345

2026-04-15

0001847345

ASBP:CommonStockParValue0.0001PerShareMember

2026-04-15

0001847345

ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember

2026-04-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 15, 2026

Aspire

Biopharma Holdings, Inc.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-41293

33-3467744

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

23150

Fashion Drive, Suite 232

Estero, Florida 33928

(Address

of Principal Executive Offices)

(415) 592-7399

(Registrant’s

Telephone Number)

194

Candelaro Drive, #233

Humacao,

PR 00791

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.0001 per share

ASBP

The

Nasdaq Stock Market LLC

Warrants,

each exercisable for one share of common stock

ASBPW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01. Entry into a Material Definitive Agreement.

Securities

Purchase Agreement

previously reported, on February 6, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) entered into a

securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the

“Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the

“Offering”), up to 25,000 shares (the “Shares”) of the Company’s newly-designated Series

A Convertible Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), which Preferred Stock

is convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common

Stock”) as more fully described in the Certificate of Designations, Preferences and Rights of the Series A Convertible

Preferred Stock, as amended (the “Certificate of Designation”).

Pursuant

to the Certificate of Designation, which was filed as Exhibit 3.1 to the Current Report on Form 8-K filed by the Company on February

6, 2026, subject to Stockholder Approval (as defined below, and which has been obtained on April 10, 2026), each share of Preferred Stock is

convertible at the option of the holder into shares of Common Stock at a conversion price equal to 80% of the lowest closing price of

our Common Stock as of the closing of the Principal Market (as such term is defined in the Certificate of Designation) for each of the

five (5) Trading Days (as such term is defined in the Certificate of Designation) immediately prior to the date of conversion, or other

date of determination (but in no event less than the floor price), subject to certain adjustments as set forth in the Certificate of

Designation (the “Conversion Price”). The floor price is equal to 20% of the Minimum Price (as such term is defined

by the rules and regulations of The Nasdaq Stock Market LLC under Nasdaq Listing Rule 5635(d)(1)(A)) or such lower amount as

permitted, from time to time, by the Principal Market (the “Floor Price”). The number of shares of Common Stock issuable

upon conversion of a share of Preferred Stock shall be determined by dividing (x) the stated value of the Preferred Stock to be converted

by (y) the Conversion Price.

The

shares of Preferred Stock are convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to

a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% of

the shares of Common Stock that would be issued and outstanding following such conversion (the “Maximum Percentage”). An

Investor may decrease or increase the Maximum Percentage by written notice to the Company from time to time to any other percentage not

in excess of 9.99%, provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after

such notice is delivered to the Company. The Company obtained Stockholder Approval for the conversion of the Shares in excess of 19.99%,

on April 10, 2026.

previously disclosed, pursuant to the Securities Purchase Agreement, the Company and the investors agreed to an additional tranche

of approximately $10,000,000. On April 15, 2026, the Company closed on an aggregate of 13,750 Shares resulting in gross proceeds

of $11,000,000 including the conversion of $943,801 in existing debt into Shares on the same terms, before deducting fees to be paid

to the placement agents and financial advisors of the Company and other estimated offering expenses payable by the Company.

RBW

Capital Partners, LLC, acted as placement agent for the Offering. As compensation in connection with the Offering, the Company paid the

placement agent a placement agent fee equal to $900,000.

The

Offering

The

initial closing of the issuance of Preferred Stock occurred on or February 6, 2025 (the “Initial Closing”). At the

Initial Closing, the Company issued 13,750 Shares of Preferred Stock for aggregate gross proceeds of $11,000,000 million, which

included $943,801 of debt that converted into Preferred Shares on the same terms.

Second

Closing

April 15, 2026, a second closing was completed, pursuant to which the Company issued an additional 12,500 Shares of Preferred Stock

for aggregate proceeds of $10,000,000 (the “Second Closing”). The Company’s registration statement to register

the shares of Common Stock issuable upon the conversion of the Shares was deemed effective on April 14, 2025 (File No. 333-293515),

and the Company’s shareholders approved the issuance of the additional conversion Shares on April 10, 2026.

a result of the Offering, and as of the date of this filing, the Company believes it has stockholders’ equity in excess of $2.5

million, which is the minimum requirement applicable to the Company for continued listing on The Nasdaq Capital Market. The Company awaits

Nasdaq’s formal confirmation of compliance.

The

Securities Purchase Agreement and Registration Rights Agreement contain certain representations and warranties, covenants and indemnities

customary for similar transactions. The representations, warranties and covenants contained in the Securities Purchase Agreement and

Registration Rights Agreement were made solely for the benefit of the parties to the Securities Purchase Agreement and Registration Rights

Agreement and may be subject to limitations agreed upon by the contracting parties.

The

form of the Securities Purchase Agreement and Registration Rights Agreement, are filed as Exhibits 10.1 and 10.2, respectively, to this

Current Report on Form 8-K. The foregoing summaries of the terms of the Certificate of Designation, the Preferred Stock, and the Common

Stock and the terms of the Securities Purchase Agreement and Registration Rights Agreement are subject to, and qualified in their entirety

by, the full text of such documents, where applicable, which are filed herewith or incorporated herein by reference.

statement in this report or the attached exhibits is an offer to sell or a solicitation of an offer to purchase the Company’s securities,

and no offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

Item

5.03. Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.

April 13, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware

a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Amendment”).

The

Certificate of Amendment amends the Company’s previously filed Certificate of Designation of Series A Convertible Preferred Stock,

which was originally filed on February 2, 2026.

Pursuant

to the Certificate of Amendment, the Company amended certain provisions of the Certificate of Designation, including clarifying and restating

provisions relating to the designation and number of shares of Series A Convertible Preferred Stock. As amended, the Company has designated

30,000 shares of Series A Convertible Preferred Stock, each with a par value of $0.0001 and a stated value of $1,000 per share.

Except

as expressly modified by the Certificate of Amendment, the Certificate of Designation remains in full force and effect.

The

foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the full text of the Certificate of

Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward-Looking

Statements

This

Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of

1995, including without limitation statements regarding the Company’s intended use of the net proceeds from the Offering, the filing

and timing of a resale registration statement. Actual results might differ materially from those explicit or implicit in the forward-looking

statements. Important factors that could cause actual results to differ materially include: risks associated with market conditions;

risks associated with the Company’s cash needs; and risks and uncertainties associated with the Company’s business and finances

in general; and other risks and uncertainties set forth from time to time in the Company’s filings with the Commission. Any forward-looking

statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation

to update any forward-looking statements, whether because of new information, future events or otherwise.

Item

9.01 Financial Statements and Exhibits.

Exhibit

Number

Description

3.1

Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on April 13, 2026

10.1

Form of Securities Purchase Agreement, dated February 6, 2026 by and among Aspire Biopharma Holdings, Inc. and the purchasers named therein (incorporated by reference to the current report on Form 8-K, filed on by the Company on February 12, 2026)

10.2

Form of Registration Rights Agreement, dated February 6, 2026 by and among Aspire Biopharma Holdings, Inc. and the holders named therein (incorporated by reference to the current report on Form 8-K, filed on by the Company on February 12, 2026)

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

ASPIRE

BIOPHARMA HOLDINGS, INC.

By:

/s/

Ernest Scheidemann

Ernest

Scheidemann

Chief

Financial Officer

Date:

April 16, 2026

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit 3.1

GRAPHIC

Filename: ex3-1_001.jpg · Sequence: 3

Binary file (309155 bytes)

Download ex3-1_001.jpg

GRAPHIC

Filename: ex3-1_002.jpg · Sequence: 4

Binary file (564237 bytes)

Download ex3-1_002.jpg

GRAPHIC

Filename: ex3-1_003.jpg · Sequence: 5

Binary file (191814 bytes)

Download ex3-1_003.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 22

v3.26.1

Cover

Apr. 15, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 15, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-41293

Entity Registrant Name

Aspire

Biopharma Holdings, Inc.

Entity Central Index Key

0001847345

Entity Tax Identification Number

33-3467744

Entity Incorporation, State or Country Code

Entity Address, Address Line One

23150

Fashion Drive

Entity Address, Address Line Two

Suite 232

Entity Address, City or Town

Estero

Entity Address, State or Province

Entity Address, Postal Zip Code

33928

City Area Code

(415)

Local Phone Number

592-7399

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common stock, par value $0.0001 per share

Title of 12(b) Security

Common

stock, par value $0.0001 per share

Trading Symbol

ASBP

Security Exchange Name

NASDAQ

Warrants, each exercisable for one share of common stock

Title of 12(b) Security

Warrants,

each exercisable for one share of common stock

Trading Symbol

ASBPW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_WarrantsEachExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: